IGC Pharma Reports First Quarter 2026 Financial Results with CALMA Phase 2 in the final stage, with 80% Enrollment

- Continued Advancement of CALMA Phase 2 Trial -

POTOMAC, MD / ACCESS Newswire / May 19, 2026 / IGC Pharma, Inc. (NYSE American:IGC) ("IGC" or the "Company"), a clinical-stage biotechnology company developing therapeutics and artificial intelligence ("AI-enabled") tools for Alzheimer's disease ("AD"), today announced the filing of its Quarterly Report on Form 10-Q with the U.S. Securities and Exchange Commission ("SEC") for the quarter ended March 31, 2026.

Foto: Accesswire

"During the first quarter, we continued to execute against our core priorities by advancing CALMA, expanding our clinical site network, and strengthening the AI and intellectual property components of our Alzheimer's strategy with disciplined capital allocation," said Ram Mukunda, CEO of IGC Pharma. "Our near-term focus remains on completing CALMA and deploying capital toward programs that we believe may support long-term value creation for patients and shareholders. As with all clinical-stage programs, there can be no assurance regarding trial timing, clinical outcomes, regulatory approval, or commercialization."

Clinical & Strategic Highlights (three months ended March 31, 2026)

• CALMA Clinical Progress: Continued advancement of the Phase 2 CALMA clinical trial evaluating IGC-AD1 for the treatment of agitation associated with Alzheimer's disease. The CALMA trial remains ongoing, with a target enrollment of 146 patients. Subsequent to March 2026, the Company reported approximately 80% patient enrollment in the Phase 2 CALMA clinical trial.

• Clinical Site Expansion: Added clinical research sites to the CALMA trial, including Dominion Medical Associates, Inc. within Lightship's site network, Integrative Clinical Trials, LLC in Brooklyn, New York, and Visionary Investigators Network ("VIN").

• AHA Intellectual Property: Filed utility patent applications covering the architectural framework of AHA, the Company's internally developed AI-based data harmonization system.

• IGC-AD1 Intellectual Property: Announced that the Canadian Intellectual Property Office ("CIPO") issued a Notice of Allowance covering the proprietary composition underlying IGC-AD1, the Company's Phase 2 clinical-stage program for agitation associated with AD.

Financial Summary: Focused Investment in Clinical and AI Execution (three months ended March 31, 2026)

• Accelerated Research and Development ("R&D"): R&D expenses were approximately $1.3 million, compared to approximately $997 thousand in the prior-year period. The increase was primarily attributable to the progression of the CALMA trial for IGC-AD1.

Schreibe Deinen Kommentar